Synthesis of Fe(III) Carboxylate Metal-Organic Framework Functionalized with Cetyltrimethylammonium Bromide and its Application for Loading Anti-hypertensive Drug
Abstract
Metal-Organic Frameworks (MOFs) have been comprehensively investigated as potential drug carriers. The solvent-based hydrothermal synthesis and in situ synthetic modification of Fe(III) carboxylate Metal-Organic Frameworks (MIL-88A) constructed from Iron(III) chloride hexahydrate (FeCl3.6H2O), fumaric acid and Cetyltrimethylammonium bromide (CTAB) was carried out in water. The MOF was characterized using; X-ray powder diffraction (PXRD), FT-IR spectroscopy, SEM and BET analysis. The modified MOF was applied to load an anti-hypertensive drug of the diuretics family; Amiloride hydrochloride. A high loading capacity (0.162 g/g) of the drug was observed on the CTAB modified MOF. The FT-IR analysis of the loaded MOF showed absorption bands characteristics of the drug, at 3569-3104 cm-1 and 1606 cm-1 respectively, which were attributed to v(N-H) and v(C=C) present in the drug. BET surface area of 192 m2g−1 was found in the MOF before loading. This however, decreased to 178 m2g−1 after loading of the drug. Also, the Langmuir surface area, pore volumes and diameter decreased due to incorporation of the drug molecules into pores of the MOF. The encapsulation efficiency of this MOF demonstrates that; the use of porous CTAB modified iron carboxylates as potential drug carriers could signify main progress for diuretics therapy. Keywords: Metal Organic Frameworks, MIL-88A, Amiloride hydrochloride.Downloads
Published
2020-02-09
How to Cite
Tella, A. C., Olawale, M. D., Oyediran, A. O., & Alabi, A. B. (2020). Synthesis of Fe(III) Carboxylate Metal-Organic Framework Functionalized with Cetyltrimethylammonium Bromide and its Application for Loading Anti-hypertensive Drug. Journal of Chemical Society of Nigeria, 45(1). Retrieved from http://www.journals.chemsociety.org.ng/index.php/jcsn/article/view/430
Issue
Section
Articles
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.